Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 94, Issue -, Pages 41-52Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.addr.2015.04.007
Keywords
Controlled delivery; Bone morphogenetic protein; Vascular endothelial growth factor; Platelet-derived growth factor; Fibroblast growth factor; Extracellular matrix; Integrins; Clinical translation
Categories
Funding
- European Research Council under the Advanced Grant Cytrix
- Swiss National Science Foundation [P300P3-151198]
- International Joint Research Promotion Program of Osaka University
- Swiss National Science Foundation (SNF) [P300P3_151198] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Growth factors are very promising molecules to enhance bone regeneration. However, their translation to clinical use has been seriously limited, facing issues related to safety and cost-effectiveness. These problems derive from the vastly supra-physiological doses of growth factor used without optimized delivery systems. Therefore, these issues have motivated the development of new delivery systems allowing better control of the spatiotemporal release and signaling of growth factors. Because the extracellular matrix (ECM) naturally plays a fundamental role in coordinating growth factor activity in vivo, a number of novel delivery systems have been inspired by the growth factor regulatory function of the ECM. After introducing the role of growth factors during the bone regeneration process, this review exposes different issues that growth factor-based therapies have encountered in the clinic and highlights recent delivery approaches based on the natural interaction between growth factor and the ECM. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available